

### 4.0.3 DOC Cmte minutes

#### Abdominal Aortic Aneurysm Guideline Committee – development

**Date:** 06/11/2017 – 07/11/2017

**Location:** NICE offices, Manchester

**Minutes:** Final



<b>Committee members present:</b>		
	<b>Day 1</b>	<b>Day 2</b>
Andrew Bradbury (AB) – Chair	Present for all	Present for all
Alun Huw Davies (AD)	Present from partway through item 5	Present for all
Jugdeep Dhesi (JD)	Present from partway through item 2	Present for all
Chris Hammond (CH)	Present from partway through item 2	Present for all
Mark Hampshire (MH)	Present for all	Present for all
Karen Jellett (KJ)	Present for all	Present for all
Adam Pichel (AP)	Present for all	Apologies
Tamsin Ribbons (TR)	Present for all	Apologies
Les Ruffell (LR)	Present for all	Present for all
Matthew Slater (MS)	Present for all	Present for all
Alan Huw Smith (AS)	Present from item 5	Present for all
Hazel Trender (HT)	Present for all	Present for all
Noel Wilson (NW)	Present for all	Present for all

<b>In attendance:</b>		
	<b>Day 1</b>	<b>Day 2</b>
Jamie Elvidge (JE) Senior Analyst – HE	Present for all	Present for all
Justine Karpusheff (JK) Guidelines Commissioning Manager	Present until partway through item 5	Apologies
Caroline Mulvihill (CM) Technical Adviser	Present for all	Present for all
Gareth Murphy (GM) Business Analyst	Apologies	Present from partway through item 2
Adam O’Keefe (AO) Project Manager	Present for all	Present for all
Gabriel Rogers (GR) Technical Adviser (HE)	Present for all	Present for all
Shreya Shukla (SSh)	Present for all	Apologies

### 4.0.3 DOC Cmte minutes

Technical Analyst		
Jeffrey Tabiri-Essuman (JT) Technical Analyst	Present for all	Present for all
Sue Spiers (SS) Associate Director	Present until partway through item 3 and from partway through item 5	Present for all

#### Observer:

Dmitry Pomonarev	NICE Fellow in Guideline Methodology	Present for all on both days
------------------	--------------------------------------	------------------------------

#### Apologies:

Ivan Bennett – Committee member
Jaqui Lindridge – Committee member
Sammer Tang – Committee member
Sarah Glover – NICE Information Specialist
Lisa Stone – NICE Medicines Advisor

### Day 1 Monday 6 November 2017:

#### 1. Welcome, apologies, minutes of the last meeting, declarations of interest

##### Welcome

The Chair welcomed the Committee members and attendees to day one of the thirteenth meeting of the abdominal aortic aneurysm guideline committee. The Chair welcomed Mark Hampshire (Radiographer) to the group and welcomed the observer.

##### Apologies

Apologies for the meeting were received as detailed above.

##### Objectives

The Chair outlined the main objectives of the day, which included the presentation of evidence reviews on Review Questions 8, 9, 14, and 26 in the morning, followed by Review Question 12 in the afternoon, to include a presentation of Health Economic evidence.

##### Minutes of the last meeting

The minutes were agreed as an accurate record of the previous meeting, pending removal of TR from the list of apologies.

#### 4.0.3 DOC Cmte minutes

##### Declarations of interest

Each committee member was asked to declare any new conflicts since the previous meeting.

No new interests were declared. The Chair confirmed that, having reviewed the historical declaration of interests table that the committee members present were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

##### **2. Review Question 8: What tests are effective in predicting poor and good surgical outcomes in people with unruptured abdominal aortic aneurysms?**

At the beginning of item 2, AP declared co-authorship of a study including in the evidence review for Review Question 8. This was classified as a Personal, Non-financial, Specific interest. The Chair, on advice from NICE colleagues, declared that AP could fully participate in the meeting.

SSh, introduced herself as a Technical Analyst in the Guideline Updates Team, recapped the search protocol and presented the evidence supporting Review Question 8 for the committee's consideration. No economic evidence had been identified for this question.

The committee considered the evidence presented and drafted two recommendations.

##### **3. Review Question 9: What is the accuracy of available risk assessment tools in predicting poor and good surgical outcomes in people with unruptured abdominal aortic aneurysms?**

JT recapped the search protocol and presented the evidence supporting Review Question 9 for the committee's consideration. No economic evidence had been identified for this question.

The committee considered the evidence presented and drafted one recommendation.

##### **4. Review Question 14: Is goal-directed therapy effective during the surgical repair of an unruptured abdominal aortic aneurysm? And**

##### **Review Question 26: Is goal-directed therapy effective during the surgical repair of a ruptured abdominal aortic aneurysm?**

JT recapped the search protocols and presented the evidence supporting Review Questions 14 and 26 for the committee's consideration. No economic evidence had been identified for these questions.

The committee considered the evidence presented and their clinical experience but decided not to draft any recommendations for these review questions.

##### **5. Review Question 12(a) What is the effectiveness of EVAR compared to open repair surgery in reducing morbidity and mortality in people with unruptured abdominal aortic aneurysms? – Infrarenal aneurysms**

JT recapped the search protocols and presented the clinical evidence supporting Review Question 12, focussing on infrarenal aneurysms, for the committee's consideration.

### 4.0.3 DOC Cmte minutes

AD joined the meeting partway through this item and declared the following conflict of interest: Talk in U.S. next week on the cost-effectiveness of EVAR. This was classified as Personal, Non-financial, Specific - No fees paid beyond travel which are covered by the organising committee at Veith.

JE then presented the published cost-effectiveness literature identified, followed by original Health Economic analysis conducted by the NICE team.

The committee considered the evidence presented but requested further Health Economic work be carried out before drafting recommendations. This will be presented at the next meeting.

#### 6. Next steps

The Chair thanked the committee for their input and confirmed day 2 would commence at the earlier time of 9am.

### Day 2 Tuesday 7 November 2017:

#### 1. Welcome, apologies, declarations of interest

##### Introduction

The Chair welcomed the Committee members and attendees to day two of the thirteenth meeting of the abdominal aortic aneurysm guideline committee.

##### Apologies

Apologies for the meeting were received as detailed above.

##### Objectives

The Chair outlined the main objectives of the day, which included the presentation of evidence reviews for review questions 12 and 23, the presentation of Health Economic evidence and an update on development of the Health Economic Model.

##### Declarations of interest

Each committee member was asked to declare any new conflicts since the previous meeting. No new interests were declared.

The Chair confirmed that the committee members present were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

**Review Question 12(a) What is the effectiveness of EVAR compared to open repair surgery in reducing morbidity and mortality in people with unruptured abdominal aortic aneurysms? – Infrarenal aneurysms: Drafting of recommendations**

#### 4.0.3 DOC Cmte minutes

The committee revisited the Health Economic evidence presented on this review question at the end of day one.

For the benefit of the committee, GR explained that the Technology Appraisal on Endovascular stent-grafts for the treatment of abdominal aortic aneurysms (TA167) would be stood down and replaced by this guideline upon publication and went on to explain the different legal standings of NICE clinical guidelines and technology appraisals.

#### **2. Review Question 12(b) What is the effectiveness of EVAR compared to open repair surgery in reducing morbidity and mortality in people with unruptured abdominal aortic aneurysms? – Complex aneurysms**

JT recapped the search protocols and presented the clinical evidence supporting Review Question 12, focussing on complex aneurysms, for the committee's consideration. JE then presented the published cost-effectiveness literature identified.

The committee considered the evidence presented but requested further Health Economic work be carried out before drafting recommendations.

#### **3. Review Question 23: What is the effectiveness of EVAR compared to open repair surgery in repairing ruptured abdominal aortic aneurysms?**

JT recapped the search protocols and presented the clinical evidence supporting Review Question 23 for the committee's consideration. JE presented the health economic evidence identified for this question, followed by the results of original Health Economic modelling he had conducted.

The committee discussed the evidence presented and their own clinical experiences about decided to wait to draft recommendations on this review question until further evidence is presented at the next meeting.

JE and GR explained that they will now conduct further Health Economic analysis as requested by the Committee and present their findings over the next two meetings.

#### **4. Next steps**

The Chair thanked the committee for their time and contribution to Day 2. The venue, date and time of the next meeting was confirmed:

Date of next meeting: Monday 18 and Tuesday 19 December 2017.

Location of next meeting: NICE offices, London.